20 October 2014
EMA/CHMP/601124/2014
Procedure Management and Business Support Division

Committee for medicinal products for human use (CHMP)

Agenda of meeting to be held on 20-23 October 2014

Chair: Tomas Salmonson – Vice-chair: Pierre Demolis

20 October 2014, 13:00 – 19:30, room 2A

21 October 2014, 09:00 – 19:30, room 2A

22 October 2014, 09:00 – 19:30, room 2A

23 October 2014, 09:00 – 15:00, room 2A

Note on access to documents

Some documents mentioned in the agenda/minutes cannot be released at present following a request for access to documents under Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Health & Safety Information

In accordance with the Agency's Health and Safety policy, delegates are to be briefed on health & safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this agenda is considered commercially confidential and therefore not disclosed. With regards to therapeutic indications listed against products it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. The procedures discussed by the CHMP are on-going and therefore are considered confidential. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available. For orphan medicinal products the applicant details are published as this information is already publicly available. Of note, this agenda is a working document primarily designed for CHMP members and the work the Committee undertakes.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5505
Send a question via our website www.ema.europa.eu/contact

Further information with relevant explanatory notes can be found at the end of this document.

For adoption

Agenda (EMA/CHMP/601124/2014 Rev.0) and Annex to CHMP agenda of the CHMP plenary session to be held 20-23 October 2014.	
Timeschedule (EMA/CHMP/ /2014 Rev.0) of the CHMP plenary session to be held 20-23 October 2014.	
Minutes (EMA/CHMP/ /2014 Rev.0) of the CHMP plenary session held 22-25 September 2014	
Minutes (EMA/CHMP//2014) of the October 2014 CHMP and ORGAM meeting held on 13 October 2014 (EMA/CHMP/ /2014 Rev.0).	

For information

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CHMP plenary session to be held on 20-23 October 2014.	*See October 2014 Minutes (to be published post November 2014 CHMP meeting)*
Draft Agenda of 17-20 November 2014 CHMP meeting	

Table of contents

Note on access to documents 1
Health & Safety Information 1
Disclaimers 1
Table of contents 3
1. Oral explanations 6
1.1. Pre-authorisation procedure oral explanations 6
1.2. Re-examination procedure oral explanation 6
1.3. Post-authorisation procedure oral explanation 6
1.4. Referral procedure oral explanation 6
2. New full applications 6
2.1. New full applications; Opinions 6
2.2. New full applications; Day 180 List of outstanding issues 7
2.3. New full applications; Day 120 List of Questions 8
2.4. Update on on-going new full applications for Centralised procedure 8
2.5. Products in the Decision Making Phase 9
3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008 9
3.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinions 9
3.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 List of outstanding issues 10
3.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of Questions 10
3.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008 10
4. Type II variations - Extension of indication procedures according to Annex I of Commission Regulation (EC) No 1234/2008 11
4.1. Type II variation; Extension of indication; Opinions or Requests for supplementary information 11
4.2. Update on on-going type II variation; extension of indications 14
5. Ancillary medicinal substances in medical devices 14
5.1. Ancillary medicinal substances in medical devices - Opinions/ List of outstanding isues / List of Questions 14

6. Re-examination procedure (new applications) under Article 9(2) of Regulation no 726/2004 15

7. Re-examination procedure (Type II variations) under Article 16 of Commission Regulation (EC) No 1234/2008 and 9(2) of Regulation (EC) No 726/2004 15

8. Withdrawal of full new application 15

9. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use) 15

10. Pre-submission issues 16

11. Post-authorisation issues 16

12. Referral procedures 17

12.1. Procedure for Centrally Authorised products under Article 20 Council Regulation (EC) No 726/2004 17

12.2. Requests for CHMP Opinion under Article 5(3) and 57 (1)p of Regulation (EC) No 726/2004 17

12.3. Procedure under Articles 5(2) and 10 of the Regulation (EC) No 726/2004 17

12.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC 18

12.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC 18

12.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC 20

12.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC 21

12.8. Procedure under Article 107(2) of Directive 2001/83/EC 21

12.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) (EC) No 1084/2003) 21

12.10. Procedure under Article 29 Regulation (EC) 1901/2006 21

12.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) No 1234/2008) 21

13. Pharmacovigilance issues 21

14. Inspections 22

14.1. GMP inspections 22

14.2. GCP inspections 22

14.3. Pharmacovigilance inspections 22

14.4. GLP inspections 22

15. Innovation Task Force 22

15.1. Minutes of Innovation Task Force: For information 22

15.2. Briefing meetings (Innovation Task Force) 22

15.3. Eligibility to EMA scientific services 23

15.4. Requests for CHMP Opinion under Article 57 (1)P of Regulation (EC) No 726/2004 23

15.5. Nanomedicine activities 23

16. Scientific Advice Working Party (SAWP) 23

17. Satellite Groups 23

17.1. Coordination Group for Mutual Recognition and Decentralised Procedures 23

18. Other Committees 24
18.1. Committee for Orphan Medicinal Products (COMP) 24
18.2. Committee for Herbal Medicinal Products (HMPC) 24
18.3. Paediatric Committee (PDCO) 24
18.4. Committee for Advanced Therapies (CAT) 24
19. Invented name issues 24
20. Any other business 24
List of participants 26
Explanatory notes 27

1. Oral explanations

1.1. Pre-authorisation procedure oral explanations

(EMEA/H/C/003687), (naltrexone / bupropion), (indicated for the management of obesity) List of Outstanding Issues adopted on 24.07.2014. List of Questions adopted on 20.02.2014.	Possible Oral explanation to be held on Tuesday 21 October 2014 at 9.00

1.2. Re-examination procedure oral explanation

1.3. Post-authorisation procedure oral explanation

1.4. Referral procedure oral explanation

GVK Biosciences (EMEA/H/A-31/1408) Rapporteur: Harald Enzmann, Co-Rapporteur: Christian Schneider, Article 31 procedure triggered by the European Commission concerning GVK Biosciences Private Limited (GVK Bio), Swarna Jayanthi commercial complex, Ameerpet, Hyderabad 500 038, India	Oral explanation to be held on Wednesday 22 October 2 014 at 9.00.

2. New full applications

2.1. New full applications; Opinions

(EMEA/H/C/002314), (estrogens conjugated / bazedoxifene), (treatment of oestrogen deficiency and osteoporosis) Oral explanation held on 24.09.2014. List of Outstanding Issues adopted on 26.06.2014, 20.03.2014. List of Questions adopted on 15.11.2012.	
(EMEA/H/C/004000), (duloxetine), (treatment of major depressive disorder, diabetic peripheral neuropathic pain and generalised anxiety disorder) Request for Supplementary Information adopted on 24.07.2014.	

(EMEA/H/C/003726), Orphan, (olaparib), Applicant: AstraZeneca AB (treatment of ovarian cancer)
List of Outstanding Issues adopted on 26.06.2014.
List of Questions adopted on 23.01.2014.

(EMEA/H/C/004066), (paliperidone), (treatment of schizophrenia)

(EMEA/H/C/003771), (nonacog gamma), (treatment of haemophilia B)
List of Outstanding Issues adopted on 24.07.2014.
List of Questions adopted on 20.03.2014.

- BWP Report: **For adoption**

(EMEA/H/C/002548), Orphan, (afamelanotide), Applicant: Clinuvel (UK) Limited, (treatment of phototoxicity)
List of Outstanding Issues adopted on 23.01.2014, 21.03.2013.
List of Questions adopted on 19.07.2012.

(EMEA/H/C/003971), (sevelamer), (control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis)

- Revised Day 120 List of Questions: **For adoption**
- Revised response timetable: **For adoption**

(EMEA/H/C/003968), (sevelamer), (control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis).

- Revised Day 120 List of Questions: **For adoption**
- Revised response timetable: **For adoption**

2.2. New full applications; Day 180 List of outstanding issues

(EMEA/H/C/002450), Orphan, ATMP, (ex vivo autologous corneal epithelial cells including stem cells), Applicant: Chiesi Farmaceutici S.p.A., (treatment of limbal stem cell deficiency)
List of Questions adopted on 25.07.2013.

- BWP Report: **For adoption**

(EMEA/H/C/003780), (liraglutide), (treatment of obesity)
List of Questions adopted on 22.05.2014.

- BWP Report: **For adoption**

2.3. New full applications; Day 120 List of Questions

(EMEA/H/C/003984), (bortezomib), (treatment of multiple myeloma)

(EMEA/H/C/003925), (docetaxel), (treatment of breast cancer, non small cell lung cancer, prostate cancer, metastatic gastric adenocarcinoma and head and neck cancer)

(EMEA/H/C/003820), (pembrolizumab), (treatment of melanoma)

- BWP Report: **For adoption**

(EMEA/H/C/003822), Orphan, (glycerol phenylbutyrate), Applicant: Hyperion Therapeutics Limited, (treatment of patients with urea cycle disorders)

(EMEA/H/C/003858), (insulin human), (treatment of diabetes)

- BWP Report: **For adoption**

2.4. Update on on-going new full applications for Centralised procedure

(EMEA/H/C/002801), Orphan, ATMP, (allogeneic t cells genetically modified to express suicide gene), Applicant: MolMed SpA (treatment in haploidentical haematopoietic stem cell transplantation)
List of Questions adopted on 24 July 2014.

- Letter from the applicant dated 30 September 2014 requesting extension of timeframe to submit responses to Day 120 List of Questions : **For information**

(EMEA/H/C/002661), Orphan
(recombinant l-asparaginase), Applicant: medac Gesellschaft fuer klinische Spezialpraeparate mbH, (combination therapy for B/T cell lymphoblastic leukaemia (ALL) or B/T cell lymphoblastic lymphoma (LBL))

- Letter from the applicant dated requesting extension of clock-stop to responds to the Day 120 List of Questions adopted in April 2014: **For information**

(EMEA/H/C/003702), (phenylephrine hydrochloride / ketorolac trometamol), (maintenance of mydriasis, prevention of miosis and reduction of ocular pain
replacement (ILR).)
List of Outstanding Issues adopted on 22.05.2014.
List of Questions adopted on 23.01.2014.

- Revised List of Questions to Ad hoc expert group meeting : **For adoption**

2.5. Products in the Decision Making Phase

Cyramza (EMEA/H/C/002829), Orphan, (ramucirumab), Applicant: Eli Lilly Nederland B.V., (treatment of gastric cancer)
New active substance (Article 8(3) of Directive No 2001/83/EC)
List of Outstanding Issues adopted on 26.06.2014.
List of Questions adopted on 23.01.2014.

- Final Product Information: **For information**

3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

3.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinions

No items

3.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 List of outstanding issues

Orfadin (EMEA/H/C/000555/X/0041), Orphan, (nitisinone), MAH: Swedish Orphan Biovitrum International AB, Rapporteur: Luca Pani, PRAC Rapporteur: Carmela Macchiarulo "To add an oral suspension 4 mg/ml as additional pharmaceutical form"
List of Questions adopted on 19.12.2013.

3.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of Questions

Norvir (EMEA/H/C/000127/X/0127), (ritonavir), MAH: AbbVie Ltd., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Sabine Straus, "line extension of a new oral powder formulation of Norvir (ritonavir) as a replacement for the currently marketed Norvir oral solution for a more suitable ritonavir formulation for the paediatric population."

3.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008

No items

4. Type II variations - Extension of indication procedures according to Annex I of Commission Regulation (EC) No 1234/2008

4.1. Type II variation; Extension of indication; Opinions or Requests for supplementary information

Ceprotin (EMEA/H/C/000334/II/0079), (human protein c), MAH: Baxter AG, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Update of sections 4.1, 4.2 and 5.1 of the SmPC in order to extend the indication to treatment of patients with Purpura fulminans due to severe acquired protein C deficiency with consequential updates of sections 4.8 and 5.2. Additionally, section 4.6 information has been revised. The PL is updated accordingly. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 9.0."

Humira (EMEA/H/C/000481/II/0134), (adalimumab), MAH: AbbVie Ltd., Rapporteur: Kristina Dunder, Co-Rapporteur: Daniela Melchiorri, PRAC Rapporteur: Ulla Wändel Liminga, "Extension of Indication to add treatment of chronic plaque psoriasis in children and adolescents from 4 years of age, based on data from study M04-717 'A multicentre, randomised, double-dummy, double-blind study evaluating two doses of adalimumab versus methotrexate in paediatric subjects with chronic plaque psoriasis.' As a consequence sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC have been updated and the Package Leaflet has been updated accordingly. In addition, the MAH proposed minor editorial changes in the SmPC and Package Leaflet.
A revised RMP version 11.2 was included as part of this application."

Kalydeco (EMEA/H/C/002494/II/0027), Orphan, (ivacaftor), MAH: Vertex Pharmaceuticals (U.K.) Ltd., Rapporteur: Concepcion Prieto Yerro, Co-Rapporteur: Melinda Sobor, PRAC Rapporteur: Miguel-Angel Macia "Extension of indication for Kalydeco to include the treatment of cystic fibrosis in patients aged 18 years and older who have a R117H mutation in the CFTR gene. Consequently, changes are proposed to sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC and to the Package Leaflet."

Prevenar 13 (EMEA/H/C/001104/II/0111), (pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)), MAH: Pfizer Limited, Rapporteur: Kristina Dunder, Co-Rapporteur: Daniel Brasseur, PRAC Rapporteur: Qun-Ying Yue, "Extension of indication to add "pneumonia" to the authorised indication for adults (≥18 years of age), based on data from the recently completed Community–Acquired Pneumonia Immunization Trial in Adults (CAPiTA), which studied the efficacy of Prevenar 13 in preventing vaccine-serotype pneumococcal community-acquired pneumonia (CAP) and vaccine-serotype invasive pneumococcal disease (IPD) in adults aged 65 years and older. As a consequence the MAH proposes to update sections 4.1, 4.8 and 5.1 of the SmPC and to update the Package Leaflet accordingly. The provision of the CAPiTA study addresses MEA 045."

Rebetol (EMEA/H/C/000246/II/0074), (ribavirin), MAH: Merck Sharp & Dohme Limited, Rapporteur: Joseph Emmerich, "Change of the indication of Rebetol to reflect that ribavirine is indicated in the treatment of hepatitis C in combination with other medicinal products and remove reference to the peginterferon used (2a or 2b) in line with the PRAC recommendation in the PSUR assessment (EMEA/H/C/PSUSA/000100007/201307). As a consequence, sections 4.1, 4.2, 4.3, 4.4, 4.7, 4.8, 4.9 and 5.1 of the SmPC are updated. The package leaflet is updated accordingly."

Sustiva (EMEA/H/C/000249/II/0126/G), (efavirenz), MAH: Bristol-Myers Squibb Pharma EEIG, Rapporteur: Bruno Sepodes, Co-Rapporteur: Filip Josephson, PRAC Rapporteur: Margarida Guimarães, “Grouped variation consisting of two consequential variations. A type II variation to extend the therapeutic indication to include children 3 months of age to less than 3 year of age and weighing at least 3.5kg. A type IB, consequential to this update, to remove the Oral Solution pharmaceutical form for Sustiva (efavirenz) and as such upgrade the already approved “capsule sprinkle” dosing method as primary means of dosing for young patients and those that cannot swallow capsules and/or tablets” Request for Supplementary Information adopted on 22.05.2014.	
Tamiflu (EMEA/H/C/000402/II/0110/G), (oseltamivir), MAH: Roche Registration Ltd, Rapporteur: Outi Mäki-Ikola, Co-Rapporteur: Bruno Sepodes, , “A group of a type II extension of indication to include the treatment of influenza in infants below one year of age and a type IAIN to add a 3 ml plastic oral dispenser (for the Tamiflu 6mg/ml strength)”	
Teysuno (EMEA/H/C/001242/II/0018), (tegafur / gimeracil / oteracil), MAH: Nordic Group B.V., Rapporteur: Pieter de Graeff, PRAC Rapporteur: Sabine Straus, “Update of sections 4.1, 4.2 and 5.1 of the SmPC in order to add combination therapy of Teysuno with oxaliplatin (with or without epirubicin) with consequential updates to sections 4.3, 4.4, 4.5, 4.6, 4.8. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to bring the PI in line with the latest QRD template version 9.0.”	

Xtandi (EMEA/H/C/002639/II/0008), (enzalutamide), MAH: Astellas Pharma Europe B.V., Rapporteur: Arantxa Sancho-Lopez, Co-Rapporteur: Filip Josephson, PRAC Rapporteur: Dolores Montero Corominas, "Extension of indication for the treatment of adult men with metastatic castration-resistant prostate cancer who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. Consequently, changes are proposed to sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC. The package leaflet is updated accordingly. The MAH also propose to update the contact details of local representatives in the package leaflet."
Request for Supplementary Information adopted on 24.07.2014.
Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

4.2. Update on on-going type II variation; extension of indications

No items

5. Ancillary medicinal substances in medical devices

5.1. Ancillary medicinal substances in medical devices - Opinions/ List of outstanding isues / List of Questions

(EMEA/H/D/003740), (human serum albumin), , (the storage, manipulation, in-vitro culture and transfer of human gametes)
List of Questions adopted on 23.01.2014. List of Outstanding Issues adopted on25.09.2014.

- Request from the applicant for an additional extension of clock stop to respond to the List of Outstanding Issues adopted in September 2014: **For adoption**

(EMEA/H/D/002831), ((substance to be reviewed) insulin-like growth factor-i (igf-i) segment), (hard-to-heal wounds, primarily venous leg ulcers)
List of Questions adopted on 23.01.2014. List of Outstanding Issues adopted on 25.09.2014.

- Request from the applicant for an additional extension of clock stop to respond to the List of Outstanding Issues adopted in September 2014: **For adoption**

6. Re-examination procedure (new applications) under Article 9(2) of Regulation no 726/2004

No items

7. Re-examination procedure (Type II variations) under Article 16 of Commission Regulation (EC) No 1234/2008 and 9(2) of Regulation (EC) No 726/2004

No items

8. Withdrawal of full new application

No items

9. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

No items

10. Pre-submission issues

Some items in this section are considered commercially confidential or sensitive and therefore not disclosed.

(H0003954), Orphan
(Lumacaftor\Ivacaftor), Applicant: Vertex Pharmaceuticals (U.K.) Ltd., Rapporteur (treatment of Cystic Fibrosis in patients aged 12 years and older who are homozygous for the *F508del* mutation in the CFTR gene,

- Request for accelerated assessment: **For information**
- Rapporteurs' accelerated assessment briefing note: **For adoption**

Activities related to Ebola

11. Post-authorisation issues

Some items in this section are considered commercially confidential or sensitive and therefore not disclosed.

Evicel (EMEA/H/C/000898/II/0026),
(human fibrinogen / human thrombin), MAH: Omrix Biopharmaceuticals N. V., Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Update of the RMP". Oral explanation held on 22.07.2014. Request for Supplementary Information adopted on 26.06.2014, 20.03.2014.

Xofigo (EMEA/H/C/002653)
(Radium-223 Chloride), MAH: Bayer Pharma AG, Rapporteur: Harald Enzmann, Co-Rapporteur: Daniela Melchiorri, (treatment of castration-resistant prostate cancer), New active substance (Article 8(3) of Directive No 2001/83/EC)

Giotrif (EMEA/H/C/002280/II/0003),
(afatinib), MAH: Boehringer Ingelheim International GmbH, Rapporteur: Filip Josephson, "Update of section 4.4 of the SmPC to add a warning with regards to the combination of afatinib with vinorelbine in HER2 positive metastatic breast cancer further to results from a phase III clinical trial"
Request for Supplementary Information adopted on 24.07.2014.

12. Referral procedures

12.1. Procedure for Centrally Authorised products under Article 20 Council Regulation (EC) No 726/2004

Iclusig (EMEA/H/C/002695/A-20/0003)
(ponatinib), MAH: Ariad Pharma Ltd, CHMP Rapporteur: Rafe Suvarna, CHMP Co-Rapporteur: Filip Josephson, PRAC Rapporteur: Rafe Suvarna, PRAC Co-Rapporteur: Ulla Wandel-Liminga, Review of the benefit-risk balance following notification by the European Commission of a referral under Article 20(8) of Regulation (EC) No 726/2004, based on pharmacovigilance data.

- PRAC Recommendation: **For discussion**

12.2. Requests for CHMP Opinion under Article 5(3) and 57 (1)p of Regulation (EC) No 726/2004

Polymyxin-based products (EMEA/H/A-5(3)/1384)
(colistin, colistimethate), Rapporteur: Robert James Hemmings, Co-Rapporteur: Martina Weise, Review of the module 3 (quality) and European Pharmacopeia monograph. Triggered by the EMA Executive Director.

See also section 12.6 Community Interests - Referral under Article 31

- List of Outstanding Issues: **For adoption**

Activities related to Ebola

Update on Article 5(3) procedure: **For discussion**

12.3. Procedure under Articles 5(2) and 10 of the Regulation (EC) No 726/2004

No items

12.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC

Seasonique film coated tablets (EMEA/H/A-29(4)/1392)
(levonogestrel 150 µg and ethinylestradiol 30 µg / 10 µg), MAH: Teva Pharma B.V (NL), Rapporteur: Joseph Emmerich, Co-Rapporteur: Martina Weise, , RMS: FR, CMS: AT, BE, DE, IT, PL, RO, SI ,SK, Procedure number: FR/H/0516/001/DC,
Article 29(4) triggered due to disagreement with regard to the demonstration of contraceptive effectiveness and treatment compliance. Opinion adopted on 26.06.2014.

12.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC

Amoxil (EMEA/H/A-30/1372)
(amoxicillin), MAH: GlaxoSmithKline, Rapporteur: Robert James Hemmings, Co-Rapporteur: Concepcion Prieto Yerro, List of Questions adopted on 25.07.2013. List of Outstanding Issues adopted 25.04.2014.

- List of Outstanding Issues: **For adoption**

Nasonex (EMEA/H/A-30/1374)
(mometasone), nasal spray suspension, MAH: Merck Sharp & Dohme, Rapporteur: Kristina Dunder, Co-Rapporteur: David Lyons,
Nasonex was included in the list of products for SmPC harmonisation, drawn up by the CMDh, in accordance with Article 30(2) of Directive 2001/83/EC. List of Questions adopted on 19.09.2013. List of Outstanding Issues adopted on 25.09.2014, 20.02.2014.

- List of Outstanding Issues: **For adoption**

Novantrone and associated names (EMEA/H/A-30/1399) mitoxantrone), MEDA group of companies and associated companies. Rapporteur: Pieter de Graeff, Co-Rapporteur: Robert Hemmings, Harmonisation exercise for Novantrone and associated names. The review was triggered by the European Commission, due to the need of harmonisation of the Summary of Product Characteristics across Member States. • Letter from the European Commission dated 1 October 2014 notifying of an official referral under Article 30: **For information** • List of Questions : **For adoption**	Start of procedure
Plendil (EMA/H/A-30/1385) (felodipine), Astra Zeneca group of companies and associated companies, Rapporteur: Kerstin Oselin, Co-Rapporteur: Martina Weise, Harmonisation exercise for Plendil and associated names. The review was triggered by the European Commission, due to the need of harmonisation of the Summary of Product Characteristics across Member States. List of Questions adopted in 21.11.2013. List of Outstanding Issues adopted on 25.04.2014, 24.07.2014. • Opinion: **For adoption**	

Article 30 list for SmPC harmonisation, to be triggered by the EC in 2015: **For adoption** Call for expression of interest in Rapporteurship: **For agreement** Letter from CMDh to EC seeking agreement on the proposed list, dated 8 October List of products identified by CMDh, with proposed starting dates Agreement letter from the EC, dated 10 October 2014 List of products: **Durogesic** (fentanyl), Janssen-Cilag Start: September 2015 **Etopophos** (etoposide phosphate), BMS Start: October 2015	

12.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC

Polymyxin-based products (EMEA/H/A-31/1383) (colistin, colistimethate), Rapporteur: Robert Hemmings, Co-Rapporteur: Joseph Emmerich, Full benefit-risk review and update and harmonisation of the product information triggered by European Commission. • Opinion: **For adoption**	See also section 12.2 Requests for CHMP Opinion under Article 5(3)
Adrenaline auto injectors (EMEA/H/A-31/1398) Rapporteur: Alars Irs, Co-Rapporteur: Robert Hemmings Article 31 triggered by the MHRA due to the lack of robust evidence that the devices deliver the adrenaline intramuscularly in all patients.	Call for nomination of experts:Radiologists and/or ultrasonographers with expertise in special imaging techniques – particularly contrast ultrasonography. Pharmacokineticists with expertise in: • PK modelling • Micro-dosing • Scintigraphy Consultant allergists, particularly in tertiary referral centres dealing with patients with severe allergies.

12.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC

No items

12.8. Procedure under Article 107(2) of Directive 2001/83/EC

No items

12.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) (EC) No 1084/2003)

No items

12.10. Procedure under Article 29 Regulation (EC) 1901/2006

No items

12.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) No 1234/2008)

Oxynal 10mg/5mg, 20mg/10mg
Targin 10mg/5mg, 20mg/10mg,
40mg/20mg, 5mg/2.5mg
(EMEA/A-13/1402)
(oxycodone/naloxone), Mundipharma GmbH, Rapporteur: Martina Weise, Co-Rapporteur: Johann Lodewijk Hillege, Mutual Recognition Procedure number: DE/H/XXXX/WS/044.
Article 13 procedure triggered by Germany on the following grounds: the benefit risk balance for the claimed indication is considered negative as the available clinical data, the proposed product information and the proposed risk minimisation measures are insufficient to assure that the risks of iatrogenic drug dependence and drug prescription abuse outweigh the benefits.

- List of Outstanding Issues / Opinion: **For adoption**

13. Pharmacovigilance issues

Summary of recommendations and advice of PRAC meeting held on 6-9 October 2014: **For information**

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for October 2014: **For adoption**	
Early Notification System: October 2014 Early Notification System on Envisaged CHMP Recommendations for Regulatory Action (based on Identified Safety Concerns) Accompanied by Communication to the General Public: **for information**	

14. Inspections

14.1. GMP inspections

Request for GMP inspections: **For adoption**	*Disclosure of information related to GMP inspections will not be published as it undermines the purpose of such inspections.*

14.2. GCP inspections

Request for GCP inspections: **For adoption**	*Disclosure of information related to GCP inspections will not be published as it undermines the purpose of such inspections.*

14.3. Pharmacovigilance inspections

Request for Pharmacovigilance inspections: **For adoption**	*Disclosure of information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections.*

14.4. GLP inspections

Request for GLP inspections: **For adoption**	*Disclosure of information related to GLP inspections will not be published as it undermines the purpose of such inspections.*

15. Innovation Task Force

15.1. Minutes of Innovation Task Force: For information

15.2. Briefing meetings (Innovation Task Force)

Disclosure of information related to briefing meetings taking place with applicants cannot be released at present time as deemed to contain commercially confidential information.

15.3. Eligibility to EMA scientific services

No items

15.4. Requests for CHMP Opinion under Article 57 (1)P of Regulation (EC) No 726/2004

Request from EDQM for EMA scientific Opinion under Art. 57 (1)P of Regulation (EC) No 726/2004 • Final Report: **For adoption**	
Draft SWP response to request from EDQM for EMA scientific Opinion under Art. 57 (1)P of Regulation (EC) No 726/2004: **For discussion**	Follow-up discussion.

15.5. Nanomedicine activities

16. Scientific Advice Working Party (SAWP)

Report from the SAWP meeting held on 6-8 October 2014. Table of conclusions: **For information**	
Scientific advice letters:	*Disclosure of information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.*

17. Satellite Groups

17.1. Coordination Group for Mutual Recognition and Decentralised Procedures

Report from the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) on the meeting held on 20-22 October 2014: **For information**	
Request from CMDh to CHMP and PDCO regarding Guidance on the development of parenteral nutrition in the paediatric population: **For information**	
QWP response to CMDh request for advice concerning the droplet size distribution of Azelastin nasal spray	

(EMA/CHMP/QWP/606171/2014): **For adoption**

- Letter from CMDh and background document: **For information**

18. Other Committees

18.1. Committee for Orphan Medicinal Products (COMP)

Press release of the COMP meeting held on 7-8 October 2014: **For information**

18.2. Committee for Herbal Medicinal Products (HMPC)

Report from the HMPC meeting held on 29-30 September 2014: **For information**

18.3. Paediatric Committee (PDCO)

PIPs reaching D30 at October 2014 PDCO: **For information**

Report from the PDCO meeting held on held on 10-12 October 2014: **For information**

18.4. Committee for Advanced Therapies (CAT)

Table of Decisions of CAT meeting held on 16-17 October 2014: **For information**

19. Invented name issues

No items

20. Any other business

Election of CHMP Co-opted member

Election of Vice Chair of Central Nervous System Working Party

Facilitation of registration of centrally authorised products in developing countries – pilot scheme: **For discussion**

Guideline on Medicinal Products for the Treatment of Alzheimer´s Disease: **For adoption** Guideline on Medicinal Products for the Treatment of Multiple Sclerosis: **For discussion**	
Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues (BMWP)(EMEA/CHMP/BMWP/42832/2005 Rev1): **For adoption** Overview of GCG comments received (EMA/772616/2014): **For information**	
Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/SWP/169430/2012): **For adoption**	
Guideline on Quality of transdermal patches (EMA/CHMP/QWP/608924/2014): **For adoption**	
Outcome from ad-hoc QWP CT on Aripiprazole API starting materials: **For discussion**	
Call for nominations for the appointment of core members for SAG HIV/viral diseases (current mandate ends in November 2014): **For information**	Nominations or confirmation of existing members should be sent by 31 October 2014.
Guideline on the use of minimal residue disease as an endpoint in chronic lymphocytic leukaemia studies (EMA/629967/2014): **For adoption for 3 months consultation**	
Reminder to use the most up to date Readers Guidance document (EMA/162093/2008)- also including information on PRAC advice/recommendation and the older population: **For information**	
Update on RMP activities and review process: **For discussion**	

List of participants

List of participants including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 20-23 October 2014 meeting.

Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

Oral explanations *(section 1)*

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 2 and 3) or referral procedures (section 12) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

New applications *(section 2)*

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 2.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 2.2 (**Day 180 List of outstanding issues**) and 2.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 2.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 2.5, **products in the decision making phase**.

Extension of marketing authorisations according to Annex I of Reg. 1234/2008 *(section 3)*

Extensions of marketing authorisations are applications for the change or addition of new strengths, formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

Type II variations - Extension of indication procedures *(section 4)*

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 3. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

Ancillary medicinal substances in medical devices *(section 5)*

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 *(section 6)*

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

Re-examination procedures *(section 7)*

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

Withdrawal of application *(section 8)*

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use) *(section 9)*

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

Pre-submission issues *(section 10)*

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

Post-authorisation issues *(section 11)*

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.

Referral procedures *(section 12)*

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found here.

Pharmacovigilance issues *(section 13)*

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

Inspections Issues *(section 14)*

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Innovation task force *(section 15)*

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found here.

Scientific advice working party (SAWP) *(section 16)*

This section refers to the monthly report from the CHMP's Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found here.

Satellite groups / other committees *(section 17)*

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmamacovigilance Risk Assessment Committee (PRAC).

Invented name issues *(section 18)*

This section list issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found here.